Eyepoint pharmaceuticals inc EYPT.US 總覽分析
EYPT 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分中等，已經有部位可以持續持有，若想建立新部位可以等待價值評分轉變為4分以上、股利提升為2分以上
EYPT 近期報酬表現
2.38%
Eyepoint pharmaceuticals inc
3.56%
同產業平均
1.47%
S&P500
與 EYPT 同產業的標的表現
- INTS Intensity therapeutics inc價值 -趨勢 1 分波段 1 分籌碼 1 分股利 1 分查看更多
EYPT 公司資訊
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company's other products include YUTIQ and DEXYCU.